DEF 14A: Disc Medicine Sets Date for 2024 Annual Stockholders Meeting

Disc Medicine will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Summary

• Disc Medicine, Inc. will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 9:00 A.M. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 15, 2024, are entitled to vote.
• The meeting will address the election of two Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and any other business properly brought before the meeting.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of the accounting firm appointment.
• The company is following the SEC's Notice and Access rule, providing proxy materials online but offering print versions upon request.
• The company had 24,721,465 shares of common stock outstanding as of April 15, 2024.
• The company is an emerging growth company and therefore has scaled disclosure requirements.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting necessary information for the annual meeting. The tone is neutral and factual, with a focus on compliance and corporate governance. The positive aspects include the virtual meeting format and commitment to board diversity.

Positives

• The virtual-only meeting format is expected to enhance stockholder access and participation.
• The company is committed to corporate governance best practices by seeking stockholder ratification of the independent auditor appointment.
• The board of directors has a nominating and corporate governance committee committed to creating a board with diversity of expertise and experience.
• The company has a clawback policy in place for recoupment of incentive compensation from executive officers in the event of a financial restatement.

Risks

• The document mentions that the company faces a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property as more fully discussed under Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Future Outlook

The document does not contain specific forward-looking statements regarding financial performance or business strategy beyond the items to be addressed at the annual meeting.

Management Comments

• The board of directors believes that submitting the appointment of EY to the stockholders for ratification is good corporate governance.
• We are utilizing a virtual-only meeting format in order to leverage technology to enhance stockholder access to the Annual Meeting by enabling attendance and participation from any location around the world.
• We believe that the virtual-only meeting format will give stockholders the opportunity to participate fully and equally, and without cost, and to exercise the same rights as if they had attended an in-person meeting.

Industry Context

As a publicly traded company in the biotechnology sector, Disc Medicine's annual meeting and proxy statement are standard practices for corporate governance, ensuring transparency and stockholder participation in key decisions. The virtual meeting format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is generally in line with industry practices for similarly sized biotechnology companies.
• The company's audit committee composition and responsibilities align with Sarbanes-Oxley Act requirements and Nasdaq listing standards.
• The company's clawback policy is in compliance with the Dodd-Frank Wall Street Reform and Consumer Protection Act and applicable Nasdaq listing standards.
• The company's board diversity policy is consistent with Nasdaq's board diversity rule.

Management Changes

Corporate Governance

Related Party Transactions

• In June 2023, Disc Medicine completed an underwritten public offering and sale of common stock and pre-funded warrants, with AI DMI LLC, an affiliate of Access Industries Management, purchasing pre-funded warrants for an aggregate total purchase price of $9,999,949.
• In February 2023, Disc Medicine entered into a securities purchase agreement with certain investors, including Bain Capital Life Sciences Opportunities III, L.P., entities affiliated with OrbiMed Advisors LLC, and AI DMI LLC, who are beneficial holders of more than 5% of Disc Medicine's capital stock.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions, including the election of directors and the ratification of the independent auditor.
• The virtual meeting format enhances accessibility for all shareholders, regardless of location.
• The company's commitment to corporate governance and ethical conduct benefits all stakeholders, including employees, customers, and suppliers.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 12, 2024.
• The company will announce preliminary voting results at the Annual Meeting and file a Form 8-K with final results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Ernst & Young, Auditor Ratification, Corporate Governance, Disc Medicine